DAWN Revenue fourth quarter 2025 Y/Y Growth Comment
Day One Biopharmaceuticals Inc reported Revenue surge of 83.9% year on year in the fourth quarter 2025, to $ 53.72 millions, this is lower than Day One Biopharmaceuticals Inc 's recent average Revenue surge of 113.42%.
Looking into fourth quarter 2025 results within Major Pharmaceutical Preparations industry 53 other companies have achieved higher Revenue growth. While Day One Biopharmaceuticals Inc ' s Revenue jump of 83.9% ranks overall at the positon no. 381 in the fourth quarter 2025.
DAWN Revenue ( Y/Y Growth %)
2025
2024
2023
2022
4th Quarter
December
83.9 %
-
-
-
3rd Quarter
September
-57.55 %
-
-
-
2nd Quarter
June
314.04 %
-
-
-
1st Quarter
March
-
-
-
-
FY
20.61 %
-
-
-
Financial Statements
Day One Biopharmaceuticals Inc 's fourth quarter 2025 Revenue
Revenue by Quarter for the Fiscal Years 2022, 2023, 2024, 2025
Day One Biopharmaceuticals Inc 's Q/Q Revenue Growth
Revenue Q/Q Growth Statistics
High
Average
Low
1044.54 %
173.93 %
-68.85 %
(Sep 30 2024)
DAWN's IV. Quarter Q/Q Revenue Comment
Day One Biopharmaceuticals Inc achieved in the IV. Quarter 2025 below company average Revenue jump of 34.97% quarter on quarter, to $ 53.72 millions.
Although the IV. Quarter 2025 Revenue Q/Q growth was lower than the regular , this has been yet encouraging story, as the IV. Quarter surge, eclipses the -68.85% growth in the IV. Quarter a year ago
Within Major Pharmaceutical Preparations industry 63 other companies have achieved higher Revenue quarter on quarter growth. While Day One Biopharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 484.
Day One Biopharmaceuticals Inc achieved in the IV. Quarter 2025 below company average Revenue jump of 34.97% quarter on quarter, to $ 53.72 millions.
IV. Quarter 2025 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -68.85% in the IV. Quarter a year ago.
Within Major Pharmaceutical Preparations industry 63 other companies have achieved higher Revenue quarter on quarter growth. While Day One Biopharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 484.
Day One Biopharmaceuticals Inc 's 12 Months Revenue Growth Year on Year
Revenue TTM Growth
12 Months Ending (Dec 31 2025)
12 Months Ending (Sep 30 2025)
12 Months Ending (Jun 30 2025)
12 Months Ending (Mar 31 2025)
12 Months Ending (Dec 31 2024)
Cumulative Revenue 12 Months Ending
$ 158.18
$ 133.67
$ 187.64
$ 161.92
$ 0.00
Y / Y Revenue Growth (TTM)
-
-
-
-
-
Year on Year Revenue Growth Overall
Ranking
#
#
#
#
#
Seqeuential Revenue Change (TTM)
18.34 %
-28.76 %
15.88 %
-
-
Seq. Revenue Growth (TTM) Overall
Ranking
# 787
# 797
# 0
# 0
# 0
Cumulative Revenue growth Comment
Day One Biopharmaceuticals Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 83.9% year on year, to $ 158 millions if the fiscal year would have ended in Dec 31 2025. Day One Biopharmaceuticals Inc 's trailing twelve months Revenue growth was higher than company's average 0% and higher than % growth in Sep 30 2025. And, Day One Biopharmaceuticals Inc realized the fastest Revenue growth, in Major Pharmaceutical Preparations industry. But from twelve months ended Sep 30 2025 rise was beneth at 18.34 % from $133.67 millions achieved in the period from Sep 30 2025 to Dec 31 2024. Still this was evidence of convincing trend, while the usual Q/Q TTM gain stands at 0%. The momentum is even more impressive from twelve months ended Sep 30 2025 exhibited at 18.34 % increase from $133.67 millions in the period from Sep 30 2025 to Dec 31 2024.
Day One Biopharmaceuticals Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .
Day One Biopharmaceuticals Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 83.9% year on year, to $ 158 millions if the fiscal year would have ended in Dec 31 2025. Day One Biopharmaceuticals Inc 's trailing twelve months Revenue growth was higher than company's average 0% and higher than % growth in Sep 30 2025. And, Day One Biopharmaceuticals Inc realized the fastest Revenue growth, in Major Pharmaceutical Preparations industry. But from twelve months ended Sep 30 2025 rise was beneth at 18.34 % from $133.67 millions achieved in the period from Sep 30 2025 to Dec 31 2024. Still this was evidence of convincing trend, while the usual Q/Q TTM gain stands at 0%. The momentum is even more impressive from twelve months ended Sep 30 2025 exhibited at 18.34 % increase from $133.67 millions in the period from Sep 30 2025 to Dec 31 2024.
Day One Biopharmaceuticals Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .
About Day One Biopharmaceuticals Inc Revenue Growth Rates (DAWN), Current and Historic Growth - CSIMarket Analysis
How we calculate this
This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years).
Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.
What’s included here
Company: Day One Biopharmaceuticals Inc
(CIK 1845337).
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
144.70%